Not sure; however, GILD at an EV >$150B is too risky to buy, IMO. Investors aren’t sufficiently accounting for the inevitable erosion of GILD’s HIV franchise in the next 3-5 years because they naïvely think TAF will make everything ok. It won’t (#msg-106586262).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”